Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763898 | 0.83 | ESR1 (0.54) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6761456 | 0.83 | ESR1 (0.54) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6766605 | 0.83 | ESR1 (0.54) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6763919 | 0.83 | ESR1 (0.54) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6762181 | 0.82 | ESR1 (0.52) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6762604 | 0.81 | ESR1 (0.51) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6762576 | 0.79 | MDM2 (0.52) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL6764011 | 0.78 | MAPT (0.55) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL10355759 | 0.77 | ESR1 (0.57) | ESR1ESR2MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL796288 | 0.76 | ESR1 (0.59) | ESR1ESR2MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | VALENZUELA CORTES CARMEN MARIA (CL) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247698-A1 | Erectile Dysfunction Treatment | PDE3A, PDE3B, PDE12 | ESR1 189/4885ESR2 102/4885MAPT 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.